Details of the Drug

General Information of Drug (ID: DMI18HW)

Drug Name

Benzocaine

Synonyms

Aethoform; Americaine; Anaesthesin; Anaesthesinum; Anaesthin; Anestezin; Anesthesin; Anesthesine; Anesthone; Bensokain; Benzocaina; Benzocainum; Chloraseptic; Dermoplast; Ethoform; Ethoforme; Hurricaine; Identhesin; Keloform; Norcain; Norcaine; Norcainum; Orthesin; Otocain; Outgro; Parathesin; Parathesine; Solarcaine; Topcaine; Aethylium paraminobenzoicum; Amben ethyl ester; Anestezin [Russian]; Baby Anbesol; Benzocaine Acetate; Benzocaine Formate; Benzocaine Hydrobromide; Benzocaine Hydrochloride; Benzocaine Methanesulfonate; Ethyl PABA; Ethyl aminobenzoate; Ethylis aminobenzoas; Solu H; Acetate, Benzocaine; Anaesthan-syngala; Auralgan (TN); Benzocaina [INN-Spanish]; Benzocaine [INN:BAN]; Benzocainum [INN-Latin]; Ethyl 4-aminobenzoate; Ethyl 4-aminobenzoate hydrochloride; Ethyl aminobenzoate (JP15); Ethyl aminobenzoate (VAN); Ethyl p-aminobenzoate; Ethyl p-aminophenylcarboxylate; Ethylaminobenzoate-4; Ethylesterkyseliny p-aminobenzoove; Ethylester kyseliny p-aminobenzoove [Czech]; Formate, Benzocaine; Hydrobromide, Benzocaine; Hydrochloride, Benzocaine; Methanesulfonate, Benzocaine; Ora-jel; P-Aminobenzoic acid ethyl ester; P-Aminobenzoic ethyl ester; P-Carbethoxyaniline; P-Ethoxycarboxylic aniline; Parathesin (TN); AE-562/40377256; Benzocaine (USP/INN); ETHYL-P-AMINOBENZOATE; P-(Ethoxycarbonyl)aniline;P-Aminobenzoic acid, ethyl ester; Benzoic acid, amino-, ethyl ester; H-4-abz-oet; Benzoic acid, 4-amino-, ethyl ester; Benzoic acid, p-amino-, ethyl ester; Benzoic acid, 4-amino-, ethyl ester, hydrochloride; 112909_ALDRICH; 112909_SIAL; 4 Aminobenzoic Acid Ethyl Ester; 4-(Ethoxycarbonyl)aniline; 4-Aminobenzoic acid ethyl ester; 4-Aminobenzoic acid, ethyl ester; 4-Carbethoxyaniline; 4-amino-benzoic acid ethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[1]

Therapeutic Class

Anesthetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

165.19

Topological Polar Surface Area (xlogp)

1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Metabolism: The drug is metabolized via the ester hydrolysis to form 4-aminobenzoic acid, acetylation to form acetylbenzocaine, or N-hydroxylation to form benzocaine hydroxide [2]

Chemical Identifiers

Formula: C9H11NO2
IUPAC Name: ethyl 4-aminobenzoate
Canonical SMILES: CCOC(=O)C1=CC=C(C=C1)N
InChI: InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
InChIKey: BLFLLBZGZJTVJG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2337
ChEBI ID: CHEBI:116735
CAS Number: 94-09-7
DrugBank ID: DB01086
TTD ID: D0Q8ZX
VARIDT ID: DR00662
ACDINA ID: D00061

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 27	E00381	83511	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sucralose	E00370	71485	Flavoring agent
Crospovidone	E00626	Not Available	Disintegrant
Magnesium stearate	E00208	11177	lubricant
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
--------------------


⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Benzocaine 6 mg tablet	6 mg	Disintegrating Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res. 1999 Jul;7(4):370-8.
2	Nobilis M, Mikusek J, Szotakova B, Jirasko R, Holcapek M, Chamseddin C, Jira T, Kucera R, Kunes J, Pour M: Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites. J Pharm Biomed Anal. 2013 Jun;80:164-72. doi: 10.1016/j.jpba.2013.03.006. Epub 2013 Mar 19.
3	Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94.
4	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
5	Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
6	Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
7	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
8	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
9	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
10	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
13	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.